COVID-19 and cholesterol biosynthesis: Towards innovative decision support systems.

COVID-19 and cholesterol biosynthesis: Towards innovative decision support systems.

Publication date: Oct 20, 2023

With COVID-19 becoming endemic, there is a continuing need to find biomarkers characterizing the disease and aiding in patient stratification. We studied the relation between COVID-19 and cholesterol biosynthesis by comparing 10 intermediates of cholesterol biosynthesis during the hospitalization of 164 patients (admission, disease deterioration, discharge) admitted to the University Medical Center of Ljubljana. The concentrations of zymosterol, 24-dehydrolathosterol, desmosterol, and zymostenol were significantly altered in COVID-19 patients. We further developed a predictive model for disease severity based on clinical parameters alone and their combination with a subset of sterols. Our machine learning models applying 8 clinical parameters predicted disease severity with excellent accuracy (AUC = 0. 96), showing substantial improvement over current clinical risk scores. After including sterols, model performance remained better than COVID-GRAM. This is the first study to examine cholesterol biosynthesis during COVID-19 and shows that a subset of cholesterol-related sterols is associated with the severity of COVID-19.

Open Access PDF

Concepts Keywords
Biomarkers Bioinformatics
Dehydrolathosterol Lipid


Type Source Name
disease MESH COVID-19
pathway REACTOME Cholesterol biosynthesis
drug DRUGBANK Tropicamide
drug DRUGBANK Cholesterol
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)